FealtySign in

HEALTHPEAK PROPERTIES, INC.

(DOC)

CIK 765880 · SEC filings only

Not gradedDividend record
shown as history
company entity
59 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

59 declarations · 9 raised · 47 held · 2 cut · held 16 quarters

  1. HELD$0.3050/shperiod ended 2026-06-30Filing ↗
  2. HELD$0.3050/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.3050/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.3050/shperiod ended 2025-06-30Filing ↗
  5. RAISED$0.3050/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.3000/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.3000/shperiod ended 2024-06-30Filing ↗
  8. HELD$0.3000/shperiod ended 2024-03-31Filing ↗
  9. HELD$0.3000/shperiod ended 2023-09-30Filing ↗
  10. HELD$0.3000/shperiod ended 2023-06-30Filing ↗
  11. HELD$0.3000/shperiod ended 2023-03-31Filing ↗
  12. HELD$0.3000/shperiod ended 2022-09-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
2 resolved promises

Not enough resolved promises to grade

2 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Open promises (2)

Open · buyback authorization

new $500 million share repurchase authorization

next filing due$500.0Mreceipt (opens in a new tab)
Open · buyback authorization

Healthpeak's Board of Directors authorized a new $500 million share repurchase program

resolves in ~646 days$500.0Mreceipt (opens in a new tab)

Credibility timeline

PARTIAL · Oct 25, 2024PARTIAL · Feb 4, 2025
20242025
Timeline as a list
  • Oct 25, 2024PARTIALHealthpeak’s Board of Directors approved a $500 million share repurchase program
  • Feb 4, 2025PARTIALHealthpeak’s Board of Directors approved a share repurchase program authorizing Healthpeak to purchase up to $500 million of common stock
2 resolved buyback promises · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
Not yet gradedGuidance record
harness minimum not met
company entity
0 resolved promises

Sector median (Real Estate & Construction): A across 6 graded companies

Not enough comparable guidance to grade

0 of the 4 resolved guidance promises needed to publish a reliability grade. Some of this company’s guidance has no reported figure we can compare it with. It is shown below, never scored; the line under each statement says why. Here's what we're tracking — we never show a grade we can't back with receipts.

Pro

guidance history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

7 of 7 guidance figures that were graded or dropped for basis could not be graded on the same basis (100%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
Revenue · basis not stated5005
EPS · non-GAAPcannot be graded3012
EPS · basis not statedcannot be graded230617

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (31)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. eps guidance fy · May 5, 2026
    Diluted earnings per common share from $0.34 – $0.38 to $0.46 – $0.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Feb 2, 2026
    Diluted earnings per common share from $0.34 – $0.38
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Oct 23, 2025
    Diluted earnings per common share from $0.25 – $0.31 to $0.00 – $0.06
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. revenue guidance fy · Oct 23, 2025
    Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.0% – 4.0%
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  5. eps guidance fy · Jul 24, 2025
    Diluted earnings per common share from $0.30 – $0.36 to $0.25 – $0.31
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Apr 24, 2025
    Diluted earnings per common share of $0.30 – $0.36
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Feb 3, 2025
    Diluted earnings per common share of $0.30 – $0.36
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Oct 24, 2024
    Diluted Nareit FFO per share from $1.59 – $1.63 to $1.61 – $1.63
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Oct 24, 2024
    Diluted FFO as Adjusted per share from $1.77 – $1.81 to $1.79 – $1.81
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Oct 24, 2024
    Diluted AFFO per share from $1.54 – $1.58 to $1.56 – $1.58
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Oct 24, 2024
    Diluted earnings per common share from $0.27 – $0.31 to $0.40 – $0.42
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Jul 25, 2024
    Diluted earnings per common share from $0.16 – $0.20 to $0.27 – $0.31
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Apr 25, 2024
    Diluted earnings per common share from $0.07 – $0.13 to $0.16 – $0.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Feb 8, 2024
    Diluted earnings per common share of $0.07 – $0.13
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Oct 30, 2023
    Diluted earnings per common share from $0.49 – $0.53 to $0.53 – $0.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Jul 27, 2023
    Diluted earnings per common share from $0.52 – $0.58 to $0.49 – $0.53
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Apr 27, 2023
    Diluted earnings per common share of $0.52 – $0.58
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Feb 7, 2023
    Diluted earnings per common share of $0.52 – $0.58
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Nov 1, 2022
    Diluted earnings per common share from $0.97 – $1.03 to $0.94 – $0.96
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · Aug 2, 2022
    Diluted earnings per common share from $0.58 – $0.64 to $0.97 – $1.03
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · May 3, 2022
    Diluted earnings per common share of $0.58 – $0.64
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · Feb 8, 2022
    Diluted earnings per common share of $0.58 – $0.64
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. revenue guidance fy · Feb 8, 2022
    Total Portfolio Same-Store Cash (Adjusted) NOI growth of 3.25% – 4.75%
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  24. eps guidance fy · Nov 2, 2021
    Diluted earnings per common share from $0.95 – $1.01 to $0.94 – $0.98
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. revenue guidance fy · Nov 2, 2021
    Blended Total Portfolio Same-Store Cash (Adjusted) NOI growth from 2.25% – 3.75% to 3.50% – 4.00%
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  26. eps guidance fy · Aug 3, 2021
    Diluted earnings per common share from $0.98 – $1.06 to $0.95 – $1.01
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. revenue guidance fy · Aug 3, 2021
    Blended Total Portfolio Same-Store Cash (Adjusted) NOI growth from 1.75% – 3.25% to 2.25% – 3.75%
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  28. eps guidance fy · May 4, 2021
    Diluted earnings per common share from $1.02 – $1.12 to $0.98 – $1.06
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. revenue guidance fy · May 4, 2021
    Blended Total Portfolio Same-Store Cash (Adjusted) NOI growth from 1.50% – 3.00% to 1.75% – 3.25%
    Not judged — the company guided on a basis or for a measure that the reported figure we hold does not match.Filing ↗
  30. eps guidance fy · Feb 9, 2021
    Diluted earnings per common share of $1.02 to $1.12
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance fy · Feb 13, 2019
    Diluted net income per share to range between $0.45 to $0.51
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
0 resolved guidance promises · 31 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →